호흡기질환 백신 시장 : 기회, 성장 촉진요인, 산업 동향 분석과 예측(2024-2032년)

Global Respiratory Disease Vaccine Market will witness a 4.1% CAGR from 2024 to 2032, driven by increasing respiratory disease incidences and significant advancements in vaccine technology. The surge in respiratory conditions, such as influenza, COVID-19, and respiratory syncytial virus (RSV, is raising the demand for effective vaccines. The emergence of new respiratory pathogens and the ongoing threat of pandemics have heightened the need for advanced vaccines that offer robust protection. Rising approvals of new medications also support the demand. For instance, in July 2024, the vaccine Arexvy, which protects against the respiratory syncytial virus (RSV), developed by British pharmaceutical company GSK, was approved by the Health Sciences Authority (HSA).

Technological innovations, particularly in mRNA technology, are revolutionizing vaccine development, enabling rapid and effective responses to emerging respiratory threats. Additionally, increased public awareness and government initiatives to promote vaccination are contributing to the expansion of the respiratory disease vaccine market.

The overall Respiratory Disease Vaccine Industry is classified based on the technology, age group, infection, distribution channel, and region.

mRNA technology will play a pivotal role in the growth of the Respiratory Disease Vaccine Market. The success of mRNA vaccines in addressing COVID-19 has demonstrated their potential for rapid development and high efficacy. This technology enables the creation of vaccines that can be swiftly adapted to new strains of respiratory viruses, offering a flexible and timely response to emerging threats. mRNA vaccines work by instructing cells to produce a protein that triggers an immune response, providing protection against specific pathogens. The scalability, speed, and precision of mRNA technology will drive significant advancements in respiratory disease vaccines, meeting the growing demand for effective and adaptable solutions.

The pediatric segment will capture a notable share of the Respiratory Disease Vaccine Market. Vaccination programs targeting children are crucial for controlling the spread of respiratory diseases and protecting vulnerable populations. With the increasing focus on early childhood immunization and the rising prevalence of respiratory infections among children, there is a growing demand for vaccines specifically designed for this age group. Pediatric vaccines are being developed to address a range of respiratory conditions, including influenza and RSV, with an emphasis on safety, efficacy, and ease of administration. This segment's growth is driven by the need to safeguard children from severe respiratory illnesses and reduce the burden on healthcare systems.

Europe will experience substantial growth in the Respiratory Disease Vaccine Market from 2024 to 2032. The region benefits from a strong healthcare infrastructure, high vaccination rates, and a proactive approach to respiratory disease prevention. European countries are investing in advanced vaccine research and development, supported by robust regulatory frameworks and government initiatives. The emphasis on public health campaigns and vaccination programs is further driving market expansion. Additionally, Europe's diverse population and high prevalence of respiratory conditions create a significant demand for innovative vaccine solutions, contributing to the overall growth of the market in the region.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of respiratory diseases
    • 3.2.1.2 Rising burden of diseases such as influenza, pneumonia, pertussis, and respiratory syncytial virus (RSV)
    • 3.2.1.3 Rising technological advancements
    • 3.2.1.4 Growing healthcare expenditure
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Complexity of developing vaccines due to evolving pathogens, increased expenses, and extended development times
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis
• 3.8 Future market trends
• 3.9 Gap analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Viral vector
• 5.3 mRNA
• 5.4 Conjugate
• 5.5 Live attenuated
• 5.6 Inactivated
• 5.7 Recombinant
• 5.8 Other technologies

Chapter 6 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Pediatric
• 6.3 Adult

Chapter 7 Market Estimates and Forecast, By Infection, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 COVID-19
• 7.3 Influenza
• 7.4 Respiratory syncytial virus (RSV)
• 7.5 Pneumonia
• 7.6 Other infections

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Other distribution channels

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AstraZeneca
• 10.2 Emergent BioSolutions Inc.
• 10.3 GSK plc.
• 10.4 Johnson and Johnson Services, Inc.
• 10.5 Merck and Co., Inc.
• 10.6 Novavax
• 10.7 Pfizer Inc.
• 10.8 Sanofi SA
• 10.9 Serum Institute of India Pvt. Ltd.
• 10.10 SINOVAC